Poolbeg Pharma PLC POLBF
Set alert
0.10 USD 0.00 0.00%
At close · Oct 29
0.095 Day range 0.095
0.0425 52-week range 0.1154
- YTD
- +125.41%
- 1 year
- +125.41%
- Open
- 0.095
- Prev close
- 0.0958
- Mkt cap
- 67.55M
- Vol
- 10.00K
- Avg vol
- 78
- EPS
- -0.01
- P/E
- 0.00
More statistics
- Low
- 0.095
- High
- 0.095
2Y chart
Signals (12)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| RSI: Overbought | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 23, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| SMA: Bullish | Feb 10, 2026 | 8 months ago |
| RSI: Overbought | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
News
- Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case
- Poolbeg secures South Korean cancer immunotherapy-induced CRS patent
- Poolbeg Pharma retains ‘buy' rating at Cavendish after safety review allows trial to continue
- Poolbeg Pharma funded to finish both trials as it courts partners for cancer drug
- Poolbeg Pharma doses eight patients in cancer side-effect trial
- Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
- Poolbeg Pharma trial progress strengthens Cavendish case for 19p target
- Poolbeg Pharma gets green light to continue clinical trial
- Poolbeg wins Israeli patent nod for lead cancer immunotherapy drug
- Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
Your note
Sign in to keep a note on POLBF — it syncs with the Stock Master app.